ArticleCancer cell international2015

Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status.

Sybil M Genther Williams et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.